IRIS
DE LUCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.069
EU - Europa 20.578
AS - Asia 9.446
SA - Sud America 1.815
AF - Africa 540
OC - Oceania 55
Continente sconosciuto - Info sul continente non disponibili 19
Totale 58.522
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.753
GB - Regno Unito 5.938
CN - Cina 3.123
IT - Italia 3.080
RU - Federazione Russa 2.984
SG - Singapore 2.848
IE - Irlanda 2.478
UA - Ucraina 1.881
BR - Brasile 1.527
FR - Francia 1.212
VN - Vietnam 1.125
DE - Germania 972
HK - Hong Kong 924
SE - Svezia 878
FI - Finlandia 526
IN - India 239
BD - Bangladesh 233
ZA - Sudafrica 231
KR - Corea 205
CA - Canada 169
NL - Olanda 142
NG - Nigeria 134
ES - Italia 117
TR - Turchia 110
AR - Argentina 100
IQ - Iraq 96
MX - Messico 81
PK - Pakistan 70
AT - Austria 67
BE - Belgio 62
PL - Polonia 60
JP - Giappone 58
ID - Indonesia 47
IR - Iran 43
AU - Australia 42
VE - Venezuela 40
CO - Colombia 39
PH - Filippine 39
EC - Ecuador 36
SA - Arabia Saudita 34
KE - Kenya 31
MA - Marocco 30
UZ - Uzbekistan 30
MY - Malesia 28
CL - Cile 26
CZ - Repubblica Ceca 26
JO - Giordania 24
AE - Emirati Arabi Uniti 21
KZ - Kazakistan 18
NP - Nepal 17
PY - Paraguay 17
EG - Egitto 16
EU - Europa 16
GR - Grecia 16
IL - Israele 15
PT - Portogallo 15
CH - Svizzera 14
LT - Lituania 14
TN - Tunisia 14
DZ - Algeria 13
ET - Etiopia 13
PE - Perù 13
JM - Giamaica 12
LB - Libano 12
AL - Albania 11
AZ - Azerbaigian 11
CI - Costa d'Avorio 11
UG - Uganda 11
UY - Uruguay 11
BG - Bulgaria 10
CR - Costa Rica 10
OM - Oman 10
PA - Panama 10
TH - Thailandia 10
HU - Ungheria 9
NZ - Nuova Zelanda 9
PS - Palestinian Territory 9
SK - Slovacchia (Repubblica Slovacca) 9
SN - Senegal 8
DO - Repubblica Dominicana 7
KG - Kirghizistan 7
LV - Lettonia 7
AO - Angola 6
DK - Danimarca 6
LU - Lussemburgo 6
TW - Taiwan 6
EE - Estonia 5
HN - Honduras 5
LK - Sri Lanka 5
NO - Norvegia 5
RS - Serbia 5
TT - Trinidad e Tobago 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
BO - Bolivia 4
BS - Bahamas 4
BW - Botswana 4
BY - Bielorussia 4
GA - Gabon 4
Totale 58.450
Salva come PNG Salva come JPEG
Città #
Southend 5.324
Fairfield 2.920
Dallas 2.661
Dublin 2.460
Ashburn 1.885
Chandler 1.802
Jacksonville 1.539
Woodbridge 1.473
Singapore 1.395
Seattle 1.157
Wilmington 1.144
Cambridge 1.025
Houston 1.015
Hong Kong 877
Moscow 730
Beijing 673
Santa Clara 663
Ann Arbor 649
San Jose 643
Menlo Park 510
Munich 496
Princeton 496
The Dalles 491
Nanjing 459
Siena 423
Helsinki 379
Los Angeles 306
Lauterbourg 304
Boardman 276
Ho Chi Minh City 269
Hanoi 256
Milan 239
New York 237
Dong Ket 229
Council Bluffs 220
Rome 204
Hefei 199
Seoul 199
Johannesburg 183
San Diego 160
Nanchang 146
Buffalo 140
Shenyang 136
São Paulo 130
Abuja 121
Redondo Beach 120
Dearborn 116
Columbus 102
Tianjin 98
Changsha 90
London 87
Hebei 86
Shanghai 76
San Mateo 74
Bologna 72
Florence 68
Jiaxing 68
Nuremberg 67
Turin 66
Orem 64
Málaga 63
Toronto 61
Frankfurt am Main 57
Chennai 56
Brussels 53
Kunming 52
Zhengzhou 51
Jinan 50
Tokyo 48
Naples 47
Norwalk 47
San Francisco 47
Chicago 46
Guangzhou 46
Ningbo 46
Izmir 45
Phoenix 43
Da Nang 42
Belo Horizonte 41
Turku 41
Vienna 40
Warsaw 40
Düsseldorf 39
Brooklyn 38
Rio de Janeiro 38
Baghdad 36
Haiphong 36
Montreal 36
Taizhou 36
Genoa 35
Atlanta 33
Lancaster 33
Dhaka 31
Falls Church 30
Stockholm 28
Tashkent 28
Nairobi 26
Hangzhou 25
Melbourne 25
Brasília 23
Totale 40.135
Salva come PNG Salva come JPEG
Nome #
Utilizzo di dalbavancina nella terapia delle infezioni osteoarticolari 1.380
Meningoencefalite da Listeria e sindrome di Miller-Fisher: un’inusuale associazione 745
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: Implications for the activity of next-line regimens from a longitudinal study in Mozambique 661
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 622
Staphylococcus aureus vaccine preclinical and clinical development: current state of the art 570
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 563
UTILIZZO DI MILTEFOSINA IN PAZIENTE CON LEISHMANIOSI MUCOSA ED INFEZIONE DA HIV 557
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 499
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study 391
AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatment. 382
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 363
An outbreak of HIV-1 subtype G among Italian injecting drug users 346
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 343
ERITEMA NODOSO RECIDIVANTE E PERSISTENTE REPLICA DI EPSTEIN-BARR VIRUS 332
Non-granulomatous cerebellar infection by Acanthamoeba spp. in an immunocompetent host 319
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 309
Nuovi approci diagnostici nelle infezioni pneumococciche: possibile ruolo della Real-time PCR e dei biomarcatori 303
A novel methodology for large-scale phylogeny partition 299
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 295
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 292
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 291
Analisi retrospettiva su infezioni invasive e non invasive da batteri Gram negativi non fermentanti in pazienti ospedalizzati 291
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 289
Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes 288
Case Report: Persistent strongyloidiasis complicated by recurrent meningitis in an HTLV seropositive Peruvian migrant resettled in Italy 285
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 283
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 283
HCMV infection in renal transplant recipients: a retrospective cohort study 281
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 280
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 277
Evolution of macrolide resistance in streptococcus pyogenes over 14 years in an area of central Italy 275
Clinical and MRI improvement in a case of progressive multifocal leukoencephalopathy 274
Un rarissimo caso di infestazione parassitaria cerebellare da Acanthamoeba spp. In soggetto immunocompetente: primo caso in Italia. 274
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 272
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 271
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 269
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 268
Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy [Sieroprevalenza dell’infezione da virus dell’epatite E (HEV) in donatori di sangue e pazienti trapiantati di rene: Uno studio retrospettivo dal centro Italia] 267
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 267
Sieroprevalenza di HEV in donatori di sangue e pazienti trapiantati di rene nella provincia di Siena. 264
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 259
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 255
Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature 254
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 251
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 250
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 245
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 245
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 244
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 237
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients 235
Un caso di “insolita” spondilodiscite da Staphylococcus capitis 235
FIBRILLO-FLUTTER IN ASSENZA DI SEGNI DI MIOCARDITE IN CORSO DI INFEZIONE DA EBV 234
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study 234
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 233
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. 229
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 229
Risposta immunitaria a lungo termine dopo vaccinazione antipneumococcica con vaccino coniugato 13-valente o vaccino polisaccaridico 23-valente in adulti HIV positivi 223
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 222
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 221
Diagnosi di sarcoidosi in nuova diagnosi di HIV 218
233. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. 214
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study 213
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads 211
High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype 210
Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion 209
MIASI CAVITARIA A LOCALIZZAZIONE NASALE DA OESTRUS OVIS: UN CASO CLINICO 209
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 208
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 208
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 208
Compartimentalizzazione di HCMV: mancata appropiatezza della sola DNAemia nella diagnosi e nella terapia di una polmonite da HCMV post-trapianto polmonare 207
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 207
Prevalence of M75 Streptococcus Pyogenes strains harboring slaa gene in patients affected by pediatric obstructive sleep apnea syndrome in Central Italy 207
Evoluzione ed efficace controllo di un vasto focolaio epidemico nosocomiale da Klebsiella pneumoniae produttrice di carbapenemasi in un’area Neurochirurgica: lezioni apprese. 206
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 206
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 206
Valutazione della risposta al test IGRA in pazienti pediatrici contatto di TBC o con sospetto clinico di infezione attiva 206
European guidelines on the clinical management of HIV-1 tropism testing 204
Un raro caso di osteomielite da Moraxella osloensis e Staphylococcus capitis in giovane paziente immunocompetente 204
Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients 202
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 201
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. 198
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load 197
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 194
La diagnosi eziologica della polmonite comunitaria: possibile ruolo della Real-Time PCR in una coorte di pazienti adulti e pediatrici 190
LA MALATTIA PNEUMOCOCCICA IN ETÀ PEDIATRICA: CONFRONTO FRA EPOCA PRE- E POST-VACCINALE 189
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 188
Gastroenteritis and Intractable Diarrhea in Newborns 188
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: A multi-cohort study 188
Meningite purulenta a decorso atipico in età pediatrica 186
A whole-genome association study of major determinants for host control of HIV-1 RID A-6681-2009 RID A-2073-2010 RID B-5656-2009 RID F-2587-2010 RID G-8810-2011 184
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 183
Long-term immune response to 13-valent Pneumococcal Conjugate Vaccine versus 23-valent Polysaccharide Vaccine in HIV-1 infected adults 182
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 181
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 181
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 181
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 179
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 179
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy 179
AIDS-related focal brain lesions in the era of highly active antiretroviral therapy RID G-8810-2011 RID A-1577-2008 178
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort 178
Totale 27.722
Salva come PNG Salva come JPEG
Categoria #
all - tutte 180.839
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 180.839
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021556 0 0 0 0 0 0 0 0 0 0 0 556
2021/20223.685 251 482 144 287 141 170 174 188 215 436 354 843
2022/20235.823 377 315 598 902 685 1.288 78 468 630 143 176 163
2023/20243.784 203 123 293 150 153 877 1.228 133 27 127 164 306
2024/20257.828 246 504 619 431 691 451 467 621 788 348 801 1.861
2025/202615.306 1.205 2.259 1.746 1.442 2.901 762 2.198 570 565 868 486 304
Totale 59.433